Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS)

Bone

Volumn 75, Issue , 2015, Pages 138-143

  Di Gregorio, S ^a,d   Del Rio, L ^a,d   Rodriguez Tolra, J ^c   Bonel, E ^a   Garcia M ^a   Winzenrieth, R ^b  

^a CETIR Grup Medic   (Spain)

^b Med Imaps   (France)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bone microarchitectural texture; Bone mineral density; Osteoporosis treatments; TBS (trabecular bone score)

Indexed keywords

ALENDRONIC ACID; CALCIUM; COLECALCIFEROL; DENOSUMAB; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; TESTOSTERONE; BONE DENSITY CONSERVATION AGENT; VITAMIN D;

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; BONE DENSITY; BONE MASS; BONE MICROARCHITECTURAL TEXTURE; BONE STRUCTURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MUSCULOSKELETAL DISEASE ASSESSMENT; OPEN STUDY; OSTEOPOROSIS; SPANIARD; TRABECULAR BONE SCORE; COMPARATIVE STUDY; DIET SUPPLEMENTATION; DRUG EFFECTS; MIDDLE AGED; PHOTON ABSORPTIOMETRY; RADIOGRAPHY;

ABSORPTIOMETRY, PHOTON; AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DENOSUMAB; DIETARY SUPPLEMENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOPOROSIS; RISEDRONATE SODIUM; TERIPARATIDE; TESTOSTERONE; VITAMIN D;

EID: 84924092870     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.12.062     Document Type: Article

References (23)

1. MacLean C., Newberry S., Maglione M., McMahon M., Ranganath V., Suttorp M., et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008, 148(3):197-213.
2. Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev Jan 23 2008, 1:CD001155.
3. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822.
4. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11(1):83-91.
5. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344(19):1434-1441.
6. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-765.
7. Chen P., Miller P.D., Delmas P.D., Misurski D.A., Krege J.H. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res Nov 2006, 21(11):1785-1790.
8. Sarkar S1., Mitlak B.H., Wong M., Stock J.L., Black D.M., Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res Jan 2002, 17(1):1-10.
9. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
10. Hans D., Barthe N., Boutroy S., Pothuaud L., Winzenrieth R., Krieg M.A. Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom Jul-Sep 2011, 14(3):302-312.
11. Winzenrieth R., Michelet F., Hans D. Three-dimensional (3D) microarchitecture correlations with 2D projection image gray-level variations assessed by trabecular bone score using high-resolution computed tomographic acquisitions: effects of resolution and noise. J Clin Densitom 2013, 16(3):287-296. [PMID:22749406].
12. Krieg M.A., Aubry-Rozier B., Hans D., Leslie W.D., Manitoba Bone Density Program Effects of anti-resorptive agents on trabecular bone score (TBS) in older women. Osteoporos Int Mar 2013, 24(3):1073-1078. [PMID:23052939].
13. Popp A.W., Guler S., Lamy O., Senn C., Buffat H., Perrelet R., et al. Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. J Bone Miner Res Mar 2013, 28(3):449-454. [PMID:23018784].
14. Petranova T., Sheytanov I., Monov S., Rashkov R., Kinov P. Efficacy of denosumab for control of bone mineral density and microarchitecture in postmenopausal women with osteoporosis: a one-year experience. Biotechnol Biotechnol Equip 2013, 27(4):3977-3981. [PMID:].
15. Senn C., Günther B., Popp A.W., Perrelet R., Hans D., Lippuner K. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int Jul 2014, 25(7):1945-1951.
16. Dufresne T.E., Chmielewski P.A., Manhart M.D., Johnson T.D., Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int Nov 2003, 73(5):423-432.
17. Snapinn S.M., Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials 2007, 8:31.
18. Thomas T., Cheung A.M., Shane E., Zanchetta J.R., Kearns A., Hans D., et al. Changes in lumbar spine QCT, DXA, and TBS in postmenopausal women with low Bone mass treated with denosumab, alendronate, or placebo 2013, ASBMR, Baltimore, USA.
19. Liu G., Peacock MD M., Eilam O., Dorulla G., Braunstein E., Johnston C.C. Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int 1997, 7(6):564-569.
20. Dufour R., Winzenrieth R., Heraud A., Hans D., Mehsen N. Generation and validation of a normative, age-specific reference curve for lumbar spine trabecular bone score (TBS) in French women. Osteoporos Int Nov 2013, 24(11):2837-2846.
21. Kolta S., Briot K., Fechtenbaum J., Paternotte S., Armbrecht G., Felsenberg D., et al. TBS result is not affected by lumbar spine osteoarthritis. Osteoporos Int Jun 2014, 25(6):1759-1764.
22. Rodriguez-Tolrà J., Toremadé J., Di Gregorio S., Del Rio L., Franco E. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology Jul 2013, 1(4):570-575.
23. Tang B.M., Eslick G.D., Nowson C., Smith C., Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50years and older: a meta-analysis. Lancet Aug 25 2007, 370(9588):657-666.